Table 1.
MBLA assessment of the clinical trial regimens compared with standard regimen
| Control (RIFHZE) | RIF20MHZ | RIF35HZE | RIF20QHZ | Rifqhz | |
| Number analysed | 32 | 18 | 17 | 16 | 16 |
| Number converted by day 56 (week 8) | 9 (28%) | 11 (61%) | 7 (41%) | 6 (38%) | 3 (19%) |
| Number converted by day 84 (week 12) | 18 (56%) | 16 (89%) | 10 (59%) | 9 (56%) | 9 (56%) |
| Median time to conversion to negative (IQR) | 77 (56–84) | 56 (42–77) | 70 (35–74) | 74 (35–84) | 70 (56–84) |
| Log-rank (Mantel-Cox) test | |||||
| HR (95% CI) | -- | 2.9 (1.3–6.7) | 2.3 (1.0–5.2) | 1.2 (0.5–2.9) | 1.1 (0.5–2.5) |
| P value | -- | 0.008 | 0.049 | 0.663 | 0.853 |
| Gehan-Breslow-Wilcoxon test | |||||
| HR (95% CI) | -- | 2.3 (1.4–6.3) | 1.9 (1.1–4.9) | 1.2 (0.5–2.8) | 1.1 (0.5–2.4) |
| P value | -- | 0.008 | 0.063 | 0.632 | 0.791 |
The RIF20MHZ and RIF35HZE treated cases had significantly shorter conversion time to negative than those treated with standard regimen.
E, Ethambutol; H, Isoniazid; M, Moxifloxacin; Q, SQ09; RIF, Rifampicin; Z, Pyrazinamide.